Related Experiment Video

Updated: Apr 30, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.3K

Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics

Bennett C Meier1, Bridget K Wagner

  • 1Chemical Biology Program, Harvard Medical School, Boston, MA, USA.

Epigenomics
|May 10, 2014
PubMed

Insights

Selective inhibition of histone deacetylase 3 (HDAC3) shows promise for treating Type 1 and Type 2 diabetes. HDAC3 inhibition protects beta cells and regulates key metabolic events, offering a potential therapeutic strategy for these metabolic diseases.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Histone deacetylase (HDAC) activity modulation is a potential therapeutic approach for various diseases.
  • Metabolic diseases, including Type 1 and Type 2 diabetes, are increasingly recognized as potential indications for HDAC inhibition.
  • HDAC3 is implicated in cellular processes relevant to diabetes pathogenesis.

Purpose of the Study:

  • To explore the therapeutic potential of selective HDAC3 inhibition in Type 1 and Type 2 diabetes.
  • To investigate the role of HDAC3 in beta-cell protection and metabolic regulation relevant to diabetes.

Main Methods:

  • Literature review of studies investigating HDAC3 activity in diabetes models.
  • Analysis of evidence linking HDAC3 to beta-cell apoptosis and metabolic gene regulation.

Main Results:

  • HDAC3 inhibition demonstrates protective effects on beta-cells against cytokine-induced apoptosis, a key factor in Type 1 diabetes.
  • HDAC3 regulates genes critical for metabolic events, suggesting a role in the pathogenesis of Type 2 diabetes.
  • Selective HDAC3 inhibition emerges as a potential therapeutic strategy for both Type 1 and Type 2 diabetes.

Conclusions:

  • Selective HDAC3 inhibition presents a promising therapeutic avenue for managing Type 1 and Type 2 diabetes.
  • Targeting HDAC3 may offer a dual benefit by protecting beta-cells and improving metabolic control.

More Related Videos

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

8.3K
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

7.5K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K